A Magnetic Resonance Spectroscopy Method in Characterization of Urine Metabolomics for Prostate Cancer

Currently, Prostate Cancer (PC) diagnosis is achieved either through invasive measures, like biopsies, or imaging techniques, such as sonography, CT, and MRI. The biomarker PSA in blood is used for screening, however its use is considered controversial. It doesn’t show to reduce PC all-cause mortality and PSA screening comes with a high number of false-positive results and associated risks. Here, using HRMAS MRS, we studied human urine samples obtained from prostate cancer patients and healthy controls to reveal potential PC-associated metabolomic changes, which may assist with early and non-invasive PC diagnosis and screening.